<DOC>
	<DOC>NCT02395133</DOC>
	<brief_summary>The primary objective of the study is to assess the ability of different dupilumab dose regimens, administered as monotherapy, to maintain the treatment response achieved after 16 weeks of initial treatment with dupilumab monotherapy compared to placebo.</brief_summary>
	<brief_title>A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Key 1. Must have completed the treatment phase in 1 of the two 16week initial treatment studies (R668AD1334 or R668AD1416). 2. Must have achieved at least 1 of the following 2 treatment success criteria: IGA = 0 or 1 (clear or almost clear) at week 16 OR EASI75 (at least 75% reduction in EASI score from baseline to week 16) 3. Must be willing and able to comply with clinic visits and studyrelated procedures 4. Must provide signed informed consent 5. Must be able to understand and complete studyrelated questionnaires Key 1. Receipt of rescue medication for AD in the initial treatment study 2. Any conditions that require permanent discontinuation of study treatment in either initial treatment study 3. Planned or anticipated major surgical procedure during the patient's participation in this study 4. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Eczema</keyword>
</DOC>